

1 Tabel 1: overzicht van de accuratessegegevens

Study	Method	Reference standard	Intervention	Tot			N			M		
				A	Se	Sp	A	Se	Sp	A	Se	Sp
Reinhardt 2006	Retrospective N=250 patients, Stage III and IV	Histopathology or follow-up > 1 year	FDG PET							93	95	90
			IdCT (with oral contrast)							84	88	74
			FDG PET/IdCT							98	98	95
Pfannenber 2007	Prospective N=64 patients, Stage III and /IV  Test interval: 1-3 days  Order of tests: not mentioned	Histopathology or other imaging follow- up or clinical follow-up > 99 days	FDG PET/IdCT	74	70	84				Lever: 65 Long: 43 Bot: 72 Subcutaneous: 79 Remaining viscera: 84	Lever: 63 Long: 26 Bot: 71 Subcutaneous: 83 Remaining viscera: 92	Lever: 100 Long: 94 Bot: 73 Subcutaneous: 65 Remaining viscera: 75
			ceCT	75	77	70				Lever: 78 Long: 80 Bot: 68 Subcutaneous: 73 Remaining	Lever: 80 Long: 96 Bot: 63 Subcutaneous: 74 Remaining	Lever: 50 Long: 24 Bot: 52 Subcutaneous: 71 Remaining

									viscera: 88	viscera: 92	viscera: 83	
			FDG PET/ceCT	87	91	77				Lever: 95 Long: 81 Bot: 88 Subcutaneous: 84 Remaining viscera: 96	Lever: 94 Long: 96 Bot: 91 Subcutaneous: 89 Remaining viscera: 100	Lever: 100 Long: 35 Bot: 80 Subcutaneous: 71 Remaining viscera: 92
			WB-MRI	79	80	76				Lever: 100 Long: 84 Bot: 100 Subcutaneous: 75 Remaining viscera: 76	Lever: 100 Long: 87 Bot: 100 Subcutaneous: 76 Remaining viscera: 62	Lever: 100 Long: 77 Bot: 73 Subcutaneous: 71 Remaining viscera: 92
Iagaru et al. 2007	Retrospective N= 106 patients; n=30  Stage III and IV	Pathology results and clinical follow-up (time period not given)	FDG PET		90	82						
			IdCT		69	94						
			FDG PET/IdCT		89	88						
Bastiaannet et al. 2009	Prospective	Histology/cytology or 6 months follow-up	FDG PET (n=203)		86	94						

	N=251; Stage III Test interval: 5 days median Order of tests: random		FDG PET/IdCT(n=48)									
			ceCT		78	94						
Veit-Haibach et al. 2009	Prospective N= 56 patients; N=12 Stage III and IV	Histopathological examination (if suspected metastases) or clinical follow-up (> 3 mo) (imaging, tumour markers, physical examination)	FDG PET					39	100		33	91
			ceCT					23	100		25	93
			FDG PET/ceCT					39	100		42	93
Laurent et al. 2010	Prospective N= 35 patients: Stage unknown Test interval: unclear Order of tests: unclear	Histology, imaging, or follow-up including tumour markers (S100, sLDH) (6 months)	FDG PET/IdCT		73	93		83	100		Bot: 71 Lever: 50 Long: 31	Bot: 100, Lever: 100 Long: 100
			DW WB-MRI		83	98		90	-		Bot: 83 Lever: 100 Long: 62	Bot: 100 Lever: 100 Long: 100
Pfluger et al. 2011	Retrospective N= 50 patients,	Histology and/or PET/CT, CT or US during follow-up (>6	FDG PET		90	88						
			neCT		62	52						

	Stage III and IV	months)	ceCT		85	63							
	Test interval: unclear		FDG PET/neCT		97	93							
	Order of tests: unclear		FDG PET/ceCT		100	93							
Jouvet et al.  2013	Prospective	Histopathology or sequential imaging during clinical follow- up (> 9 months)	FDG PET/IdCT							Lever: 100	Lever: 100	Lever: 100	
	N= 37 patients, Stage IV			86	80	93	96	96	97	Long: 64	Long: 48*	Long: 100	
	Test interval: 7 days mean									Bot:91	Bot:88	Bot:95**	
Order of tests: not mentioned								Brain:-	Brain:-	Brain:-			
			ceCT							Subcutaneous:8 0	Subcutaneous:1 00	Subcutaneous:6 3	
		81		90	70	77	96	63 <sup>#</sup>	Lever: 85	Lever: 83	Lever: 86		
									Long: 76	Long: 94*	Long:36		
			WB-MRI							Bot:85	Bot:67	Bot:100	
		70		68	73	85	96	80	Brain:96	Brain:95	Brain: 100		
										Subcutaneous:6 7	Subcutaneous:1 00	Subcutaneous:6 2	
									Lever: 78	Lever: 92	Lever: 67		
									Long: 45	Long: 26*	Long:93		

											Bot:71	Bot:100	Bot:47**
											Brain:70	Brain: 100	Brain: 100
											Subcutaneous:73	Subcutaneous:90	Subcutaneous:75
			WB-MRI + VIBE								Lever:96	Lever: 100	Lever: 93
											Long:60	Long: 52*	Long:79
				85	84	87	94	87	100#		Bot:86	Bot:100	Bot:76**
											Brain:100	Brain: 100	Brain: 100
											Subcutaneous:82	Subcutaneous:90	Subcutaneous:75

2

3 Afkortingen: A: accuratesse, Se: sensitivity, Sp: specificity, PET: positron emission tomography, PET-CT: PET/computed tomography, FDG: Fluorine-18-Fluorodeoxyglucose,  
4 WB-MRI: whole-body magnetic resonance imaging, CECT: contrast-enhanced full-dose CT, neCT: non-enhanced low-dose CT, VIBE: Volumetric interpolated breath-hold  
5 examination, US: ultrasound, \*significant verschillend van elkaar (significantieniveau niet vermeld), \*\*significant verschillend van elkaar (p<0,05), #significant verschillend van  
6 elkaar (p<0,01

